phase 3_completion
saveAstraZeneca Plc — durvalumab (Phase III Trial Completion)
community read0 votes
Therapy area: Genito Urinary System, Oncology. Indication: Bladder Cancer, Bladder Carcinoma, Kidney Cancer (Renal Cell Cancer), Metastatic Transitional (Urothelial) Tract Cancer, Renal Stones/Calculi, Transitional Cell Cancer (Urothelial Cell Cancer), Transitional Cell Carcinoma (Urothelial Cell Carcinoma), Ureter Cancer, Urethral Cancer
Data sources
globaldata
Found something off?
drug timeline · 1
same company · ±60 days · 6
- earningsASTRAZENECA PLC earningsApr 29, 2026
- fda advisory committee meetingcamizestrant: AstraZeneca Plc — camizestrant (FDA Advisory Committee Meeting)Apr 30, 2026
- phase 1 2 completionCALQUENCE: AstraZeneca Plc — Calquence (Phase I/II Trial Completion)Apr 30, 2026
- phase 2 completiontozorakimab: AstraZeneca Plc — tozorakimab (Phase II Trial Completion)Apr 30, 2026
- fda advisory committee meetingcapivasertib: AstraZeneca Plc — capivasertib (FDA Advisory Committee Meeting)Apr 30, 2026
- approvaleplontersen sodium: WAINUA (AUTOINJECTOR) (EPLONTERSEN SODIUM) — FDA approvalApr 15, 2026
related news · 7
- oncliveDurvalumab Plus BCG Reduces High-Risk NMIBC Recurrence or Death Risk by 32% in Phase 3 POTOMAC Trial
- biopharma diveBiotech leaders campaign for Pazdur; Takeda to lay off 4,500 workers
- onclivePerioperative Durvalumab Plus Neoadjuvant EV Displays EFS, OS Benefits vs SOC in MIBC
- endpointsAstraZeneca follows Merck with Phase 3 win in bladder cancer
- oncliveGU Cancer Experts Highlight Top Abstracts to Watch During ASCO 2026
- oncliveOncLive Polls Reveal Picks for Top Lung Cancer Abstracts at ASCO 2026
- oncliveTrack the Lung Cancer Abstracts That are Gaining Attention at ASCO 2026
comments(0)
5-min edit window · permanent after that